Summary of Significant Accounting Policies (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
|---|
| Accounting Policies [Abstract] |
|
| Summary of Components of Marketable Securities |
Summary
of Components of Marketable Securities
| |
|
As
of December 31, 2021 |
|
| |
|
Amortized |
|
|
Unrealized |
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Gains |
|
Losses |
|
|
Value |
|
| U.S.
government obligations |
|
$ |
650 |
|
|
$ |
17 |
|
|
$ |
- |
|
|
$ |
667 |
|
| Corporate
obligations |
|
|
8,304 |
|
|
|
- |
|
|
|
(192 |
) |
|
|
8,112 |
|
| |
|
$ |
8,954 |
|
|
$ |
17 |
|
|
$ |
(192 |
) |
|
$ |
8,779 |
|
| |
|
As
of December 31, 2020 |
|
| |
|
Amortized |
|
|
Unrealized |
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Gains |
|
Losses |
|
|
Value |
|
| U.S.
government obligations |
|
$ |
1,021 |
|
|
$ |
- |
|
|
$ |
(7 |
) |
|
$ |
1,014 |
|
| Corporate
obligations |
|
|
629 |
|
|
|
- |
|
|
|
(4 |
) |
|
|
625 |
|
| |
|
$ |
1,650 |
|
|
$ |
- |
|
|
$ |
(11 |
) |
|
$ |
1,639 |
|
|
| Schedule of Accounts Receivable Net |
Accounts
are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the
following (in thousands):
Schedule
of Accounts Receivable Net
| |
|
December
31, 2021 |
|
|
December
31, 2020 |
|
| Trade
accounts receivable |
|
$ |
18,520 |
|
|
$ |
1,975 |
|
| Unbilled
accounts receivable |
|
|
23,089 |
|
|
|
1,215 |
|
| Accounts receivable,
gross |
|
|
41,609 |
|
|
|
3,190 |
|
| Less
allowances |
|
|
(3,901 |
) |
|
|
(35 |
) |
| Total
accounts receivable |
|
$ |
37,708 |
|
|
$ |
3,155 |
|
|
| Schedule of Components of Inventory |
At
December 31, 2021 and 2020, the components of inventory are as follows (in thousands):
Schedule
of Components of Inventory
| |
|
December
31, |
|
|
December
31, |
|
| |
|
2021 |
|
|
2020 |
|
| Diagnostic
services testing material |
|
$ |
2,989 |
|
|
$ |
1,028 |
|
| Raw
materials |
|
|
1,514 |
|
|
|
1,550 |
|
| Work
in process |
|
|
260 |
|
|
|
440 |
|
| Finished
goods |
|
|
272 |
|
|
|
188 |
|
| Inventory |
|
$ |
5,035 |
|
|
$ |
3,206 |
|
| Inventory
valuation reserve |
|
$ |
(435 |
) |
|
$ |
(167 |
) |
| Inventory,
net |
|
$ |
4,600 |
|
|
$ |
3,039 |
|
|
| Schedule of Fair Value of Financial Instruments |
Schedule
of Fair Value of Financial Instruments
| |
|
As
of December 31, 2021 |
|
| |
|
Level
1 |
|
|
Level
2 |
|
|
Level
3 |
|
|
Total |
|
| Marketable
debt securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U.S.
government obligations |
|
$ |
- |
|
|
$ |
667 |
|
|
$ |
- |
|
|
$ |
667 |
|
| Corporate
obligations |
|
|
- |
|
|
|
8,112 |
|
|
|
- |
|
|
|
8,112 |
|
| Marketable
equity securities |
|
|
76 |
|
|
|
- |
|
|
|
- |
|
|
|
76 |
|
| |
|
$ |
76 |
|
|
$ |
8,779 |
|
|
$ |
- |
|
|
$ |
8,855 |
|
| |
|
As
of December 31, 2020 |
|
| |
|
Level
1 |
|
|
Level
2 |
|
|
Level
3 |
|
|
Total |
|
| Marketable
debt securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U.S.
government obligations |
|
$ |
- |
|
|
$ |
1,014 |
|
|
$ |
- |
|
|
$ |
1,014 |
|
| Corporate
obligations |
|
|
- |
|
|
|
625 |
|
|
|
- |
|
|
|
625 |
|
| |
|
$ |
- |
|
|
$ |
1,639 |
|
|
$ |
- |
|
|
$ |
1,639 |
|
|
| Schedule of Deferred Revenue |
The
following table disaggregates our deferred revenue by recognition period (in thousands):
Schedule
of Deferred Revenue
| |
|
As
of December 31, 2021 |
|
|
As
of December 31, 2020 |
|
| Recognition
Period |
|
|
|
|
|
|
|
|
| 0-12
Months |
|
$ |
2,034 |
|
|
$ |
169 |
|
| 13-24
Months |
|
|
530 |
|
|
|
84 |
|
| Over
24 Months |
|
|
375 |
|
|
|
78 |
|
| Total |
|
$ |
2,939 |
|
|
$ |
331 |
|
|
| Schedule of Disaggregation by Revenue |
The
following table disaggregates the Company’s revenue by revenue source for Fiscal 2021 and 2020 (in thousands):
Schedule
of Disaggregation by Revenue
| |
|
For
the years ended |
|
| Revenue
by Customer Type |
|
December
31, 2021 |
|
|
December
31, 2020 |
|
| Diagnostic
services |
|
$ |
68,559 |
|
|
$ |
1,277 |
|
| Contract
manufacturing |
|
|
5,786 |
|
|
|
12,252 |
|
| Retail
and others |
|
|
2,454 |
|
|
|
985 |
|
|
Genomic
products and services
|
|
|
2,243 |
|
|
|
- |
|
| Total
revenue, net |
|
$ |
79,042 |
|
|
$ |
14,514 |
|
|